aibio
Company Updates ·
BioNexus signs exclusive Malaysian healthcare licence for CogniAI
The licence is payable in BioNexus shares, and closing remains subject to technology delivery and approvals.
BGLC BioNexus Gene Lab Corp
BioNexus Gene Lab (BGLC) news
Latest BioNexus Gene Lab news
- Company Updates
BioNexus advances VitaGuard rollout in Southeast Asia
After a working visit to China, BioNexus says it is preparing the VitaGuard platform for ten licensed Southeast Asian markets.
BioNexus Gene Lab annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $7.4 million | $9.5 million |
| Research and development | $50,670 | $47,511 |
| Net income (loss) | -$3.0 million | -$1.6 million |
| Cash from operations | -$1.8 million | -$2.1 million |
| Cash and equivalents | $2.4 million | $2.9 million |
Questions about BioNexus Gene Lab
What is the ticker symbol of BioNexus Gene Lab?
BioNexus Gene Lab Corp trades under the ticker BGLC on NASDAQ.
Where is BioNexus Gene Lab listed?
BioNexus Gene Lab Corp is listed on NASDAQ.
Which country or territory is BioNexus Gene Lab listed under?
Our directory records BioNexus Gene Lab Corp under United States.
Does aibio.space cover BioNexus Gene Lab?
aibio.space lists BioNexus Gene Lab Corp among 2,820 public biotech companies and publishes its news here as stories appear.
What was BioNexus Gene Lab's revenue last year?
$7.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is BioNexus Gene Lab profitable?
BioNexus Gene Lab Corp reported a net loss of $3.0 million for the fiscal year ended Dec 31, 2025, and used $1.8 million of cash in operations, per its annual report to the SEC.
How much does BioNexus Gene Lab spend on research and development?
$50,670 in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does BioNexus Gene Lab have?
$1.2 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest BioNexus Gene Lab (BGLC) stock news?
Our latest story on BioNexus Gene Lab, dated Oct 7, 2026: "BioNexus signs exclusive Malaysian healthcare licence for CogniAI". The licence is payable in BioNexus shares, and closing remains subject to technology delivery and approvals. Source.
How long will BioNexus Gene Lab's cash last?
From our story of Oct 7, 2026: The release notes that the parties' financial condition includes going-concern uncertainties disclosed in their filings. Source.
How can I follow BioNexus Gene Lab (BGLC) news?
Press Follow on this page to add BioNexus Gene Lab to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming BioNexus Gene Lab so far, in Company Updates.
Investor discussion: BioNexus Gene Lab
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Stock chart
Listing details
- Company
- BioNexus Gene Lab Corp
- Ticker
- BGLC
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction